GALT · Company research
Galectin Therapeutics Inc. (GALT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Galectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average - Here's Why - MarketBeat | Galectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| GALECTIN THERAPEUTICS INC SEC Filing (Oct 13, 2026) - Stock Titan | GALECTIN THERAPEUTICS INC SEC Filing (Oct 13, 2026) Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - Here's Why - MarketBeat | Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 8, 2026 | neutral | 0 | 0.6 |
| Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell? - MarketBeat | Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell? MarketBeat | View source ↗ | MarketBeat | Sep 30, 2026 | neutral | 0 | 0.6 |
| Galectin Therapeutics Inc. (GALT) Key Financial Ratios – Valuation, Profitability & More - Value Research | Galectin Therapeutics Inc. (GALT) Key Financial Ratios – Valuation, Profitability & More Value Research | View source ↗ | Value Research | Sep 18, 2026 | neutral | 0 | 0.6 |
| A drug company will present in New York Sept. 14. Galectin will meet investors there. - Stock Titan | A drug company will present in New York Sept. 14. Galectin will meet investors there. Stock Titan | View source ↗ | Stock Titan | Sep 10, 2026 | neutral | 0 | 0.6 |
| Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein - Quiver Quantitative | Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 4, 2026 | neutral | 0 | 0.6 |
| $GALT stock is up 8% today. Here's what we see in our data. | GALT Stock News - Quiver Quantitative | $GALT stock is up 8% today. Here's what we see in our data. | GALT Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 13, 2026 | neutral | 0 | 0.6 |
| Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga | Top 3 Health Care Stocks That May Keep You Up At Night In June Benzinga | View source ↗ | Benzinga | Jun 30, 2026 | neutral | 0 | 0.6 |
| Should I buy Galectin Therapeutics (GALT) - Zacks Investment Research | Should I buy Galectin Therapeutics (GALT) Zacks Investment Research | View source ↗ | Zacks Investment Research | Jun 24, 2026 | neutral | 0 | 0.6 |
| GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH - Yahoo Finance | GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH Yahoo Finance | View source ↗ | Yahoo Finance | Jun 24, 2026 | neutral | 0 | 0.6 |
| Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside - Seeking Alpha | Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside Seeking Alpha | View source ↗ | Seeking Alpha | Jun 24, 2026 | neutral | 0 | 0.6 |
| GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Stocktwits | GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial Stocktwits | View source ↗ | Stocktwits | Jun 23, 2026 | neutral | 0 | 0.6 |
| Galectin Therapeutics stock surges on FDA trial agreement - Investing.com | Galectin Therapeutics stock surges on FDA trial agreement Investing.com | View source ↗ | Investing.com | Jun 23, 2026 | neutral | 0 | 0.6 |
| Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance | Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Apr 3, 2026 | neutral | 0 | 0.6 |
| Galectin Therapeutics Inc. Common Stock (GALT) Stock - Gotrade | Galectin Therapeutics Inc. Common Stock (GALT) Stock Gotrade | View source ↗ | Gotrade | Jan 19, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.